Background: Prostate cancer treatment is often accompanied by untoward side
Introduction
Prostate cancer (PCa) is the most common non-melanoma malignancy among men in the Unites States. In 2013, 238,590 new cases and 29,720 deaths related to PCa were estimated.(1) Although early screening and detection has been used historically as strategies for PCa prevention, recently these recommendations have been a subject of much debate. (2) (3) (4) The features of PCa, namely, its high prevalence and the uncertainty with regard to the effectiveness and value of early screening provide an excellent opportunity and need to develop alternate PCa control strategies. Chemoprevention to reduce the risk and inhibit the progression of PCa may be an effective approach to reduce the burden of the disease. (5) Botanicals have been shown to influence multiple biochemical and molecular cascades that inhibit mutagenesis and proliferation, induce apoptosis, and suppress the formation and growth of human cancers, thus modulating several hallmarks of carcinogenesis. Additionally, these agents appear promising in their potential to make a dramatic impact in cancer chemoprevention, with a significantly superior safety profile than most agents evaluated to date. (6) (7) (8) (9) Several epidemiological studies have demonstrated a protective effect of tea consumption against human cancers including PCa. (10) (11) (12) (13) In contrast, a few studies have associated an increased risk potentially attributed to confounding factors that include consumption of salted or very hot tea, geographical location, tobacco and alcohol use, and other dietary differences. (10, (12) (13) (14) (15) Of all the tea produced worldwide, about 20% of green tea is consumed in Asian countries such as China, Japan, Korea and India. Interestingly, these populations consistently demonstrate lower risk of PCa. (16) (17) (18) (19) (20) (21) Cancer Research. Several published preclinical studies using green tea, green tea leaves, green tea extracts (GTEs), green tea polyphenol mixtures, green tea catechin (GTC) mixtures, and individual catechins have demonstrated chemopreventive efficacy in PCa. (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) Tea and tea compounds reduce growth and/or induce apoptosis in several human cancer cell lines in vitro, including the prostate. Among the constituents of GTEs, laboratory studies have identified epigallocatechin gallate (EGCG) as the most potent chemopreventive agent which appears to affect a number of molecular processes including induction of apoptosis and inhibition of tumor growth and angiogenesis. (32) (33) (34) (35) EGCG has been found to affect several cancer-related proteins including p27, Bcl-2 or Bcr-Abl oncoproteins, Bax, matrix metalloproteinases (MMP-2 and MMP-9),(36) the androgen receptor, epidermal growth factor (EGF) receptor, activator proteins 1 (AP1), and some cell cycle regulators. (37) (38) (39) (40) By using various proteasome inhibitors, including a standardized mixture of GTCs (Polyphenon E), we and others have demonstrated that the ubiquitin/proteasome pathway plays an essential role in the regulation of apoptosis, and activation of the cellular apoptotic program and may be used as a strategy for PCa chemoprevention. (40) The safety of tea and tea compounds is supported by centuries of consumption by the human population. In four Phase I single-dose and multi-dose studies of catechins-Polyphenon E containing a dose range of 200-1200 mg EGCG has been well tolerated. (41) (42) (43) (44) In recent years, oral use of GTEs has been associated with several instances of hepatotoxicity. (45) (46) (47) (48) Most affected patients were women, and many were consuming GTEs for the purpose of weight loss. Although hepatotoxicity in most cases resolved within four months of stopping GTE, there have been cases of positive GTE (50) Although previous studies of safety had been established using other compositions of GTCs, to date, there have been no specific reports of the safety and effectiveness of Polyphenon E in reducing the progression of PCa. Although several early clinical trials have been initiated using Polyphenon E, including our clinical trial in progress, based on the available data from preclinical studies, restrictions to eligibility imposed by the FDA continue to place a significant challenge on recruitment of subjects to these trials. (5, 51) Therefore, the goal of the current study was to examine the safety and efficacy of the specific GTC mixture, Polyphenon E in reducing the progression of PCa in the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice, an established preclinical model that has been used in PCa chemoprevention studies.
Materials and Methods
Polyphenon E: Polyphenon E study drug is supplied by Mitsui Norin Co., Ltd, Japan. Polyphenon E® is a botanical drug substance containing a mixture of catechins originating from the leaves of green tea (Camellia sinensis). To manufacture Polyphenon E®, a hot water extract of green tea is extracted further with ethyl acetate.
The resulting crude extract is dissolved in methanol and purified by affinity column fractionation. Once dried, the final product contains 85-95% total catechins; the main component is EGCG, which comprises 55-72% of the material. Other catechins present Polyphenon E treatment protocol: Polyphenon E (Polyphenon Pharma, Inc. Japan) was provided ad libitum in the drinking water to three cohorts each of C57BL/6J
and TRAMP mice at one of three doses (200, 500 and 1,000 mg Polyphenon E/kg body weight/day). A fourth cohort each of C57BL/6J and TRAMP mice served as untreated controls. C57BL/6J mice were used to assess safety and for potential toxicities associated with Polyphenon E consumption. TRAMP mice were used to assess efficacy of Polyphenon E consumption to prevent prostate tumor progression to metastasis. Eight C57BL/6J and eight TRAMP mice were euthanatized after acclimation at 7 weeks of age to establish baseline clinical and histopathological findings prior to treatment, after which Polyphenon E or vehicle treatments were initiated in all other mice.
Assessments during Polyphenon E treatment were performed when mice were 12, 22 The reproductive tract and associated glands including all four lobes of the prostate were weighed and whole blood was collected. Major organs, including the lungs, heart, liver, gall bladder, spleen, pancreas, kidneys, adrenal glands, and the entire alimentary tract, including the esophagus, stomach, duodenum, jejunum, ileum, cecum, colon and the associated mesentery, and mesenteric lymph nodes were evaluated. Tissues were fixed in 10% neutral buffered formalin, dehydrated, embedded in paraffin, sectioned at 5 ㎛ and stained with H&E.
The safety of the three doses (i.e, 200, 500, and 1,000 mg/kg/day) of Polyphenon E was assessed based on clinical and anatomic pathology, including microscopic evaluation of tissues. Blood samples were taken for complete blood counts (CBC) with leukocyte differentials and serum biochemistry indicative of multi-organ functions including total protein, albumin, globulin, glucose, total bilirubin, alanine transaminase 
MRI and US analysis: Six TRAMP mice from each group (treated and untreated)
were randomly selected and monitored for tumor growth and volume by MRI or US at 32 weeks of age. Animals were induced under 3.5% isoflurane and maintained sedated during MRI and US image acquisition using 2% isoflurane. The animal's temperature was continuously monitored using a fiber optic probe and controlled using warm air.
MRI was completed on a 7 T Varian MRI spectrometer ASR310 (Agilent Life Sciences
Technologies, Santa Clara, CA) with a 30 cm bore using VNMRJ 3.1, using a Varian 72 mm quadrature coil. Axial T1 weighted images were obtained to determine the orientation of the coronal slices (using the both kidneys as a plane of reference); these images were obtained using an FSEMS (multi-slice fast spin echo) sequence with TR=600 ms, TE=8.92 ms, field of view=40 mmx40 mm, 20 slices and a matrix size of 128x128. The coronal images were obtained using an FSEMS sequence with TR 2400, 3500 or 4000 ms (depending on number of slices), effective TE=48 ms, field of view=90 Mice were placed supine on a thermo regulated platform. Pre-warmed gel was applied to cover the abdomen, and the area was manually surveyed to determine approximate size and location of the prostate. Three dimensional images were then obtained using the 3D functionality of the VEVO2100. Post-processing of the images, including calculation of prostate volume, was completed using the VEVO2100 1.1.1 software.
Measurements and images for figures were taken from images which displayed the bladder to ensure comparable anatomy and measurement sites between animals.
All MRIs and US images were taken with the same acquisition parameters between animals (to ensure same scale comparisons/measurements).
Histopathological analysis:
To assess effect of Polyphenon E on PCa progression and metastasis, each lobe of the prostate, the liver, lungs, and kidneys were subjected to histological analysis. Each lobe of prostate was evaluated separately Statistical analysis: Mean distribution-adjusted lesion grades for treated and untreated mice were compared using a Student's t-test or ANOVA and proportions were compared using a Chi-squared test. All analyses were done using Statistical Analysis System version 9.3 (SAS Institute, Inc., Cary, NC) and a P<0.05 was considered statistically significant.
Results
Cancer Research. 
Safety of Polyphenon E:
There was no noticeable toxicity with regards to mouse appearance, behavior or changes in prostate and body weights after 32 weeks of treatment for all the three doses of Polyphenon E in C57BL6J mice. As expected, the prostate and body weight of C57BL/6J mice in all three groups increased with age.
However, there was no statistically significant difference of body and prostate weights between control and treated groups (Supplemental Fig. 1A and 1B) . Further, no discernible histopathological changes were observed in the liver, lung, or any prostate lobe of C57BL/6J mice treated with the three different doses of Polyphenon E (Fig. 1A, 1B, 1C and 1D).In hematology and serum biochemistry, none of the variables were changed by long term treatment of Polyphenon E except hemoglobin. The hemoglobin levels in the treated group were increased 3-6% as compared to the control (Table 1) .
Effect of Polyphenon E on PCa development and progression:
To determine the effect of Polyphenon E on the progression of PCa, seven week old TRAMP mice were treated with three doses (i.e, 200, 500, and 1000 mg/kg/day) of Polyphenon E until 12, 22 or 32 weeks old. Similar to C57BL/6J mice, there was no statistically significant change of body and prostate weights among treated and untreated TRAMP mice (Supplemental Fig. 1C and 1D ). However, we observed a significant difference of prostate weight between untreated C57BL/6J and TRAMP mice at 32 weeks of age dose Polyphenon E during the same period ( Fig. 2A) . In addition, we observed a significant dose dependant inhibition of metastasis development with Polyphenon E treatment (P=0.0003).
Histopathological evaluation of each lobe of the prostate gland revealed contrasting differences in appearance. Histological morphology of the anterior, dorsal, lateral, and ventral lobes of the prostate gland from 32 week old C57BL/6J mice with high dose Polyphenon E treatment was normal, but significantly different compared to corresponding prostate lobes of age-matched TRAMP mice (Fig. 1E-1L ) administered the same life-long high dose of Polyphenon E. Among 59 lobes histologically evaluated in 32 week old TRAMP mice with high dose Polyphenon E treatment, prostate carcinoma were found in only 5% (3/59), while most lobes (96%, 53/59) contained either prostate epithelial hyperplasia (Fig. 1E, 1F, 1G and 1H ), or prostate adenoma (Fig. 1J,   1J , 1K and 1L). Hyperplastic prostate epithelium (Fig. 1E-1H ) of TRAMP mice was crowded, basophilic, stratified, and formed cribriform or papillary structures that projected into the lumens. Hyperplastic prostate lobes were often surrounded by proliferating smooth muscle (Fig. 1F) or fibrous connective tissue (Fig. 1H) . The prostate adenoma (Fig. 1I-1L ) in TRAMP mice occupied a significant portion of the prostate acinus lumen as a distinct mass causing distortion or compression of the surrounding glandular tissue.
Prostate cancers of untreated TRAMP mice presented as either an expansile mass of proliferating cells that invaded beyond the acinus basement membrane into the interstitium (Fig. 3A, arrow) (Fig. 3B ), or as a sheet of pleomorphic epithelial cells that invaded and surrounded glandular acini (Fig. 3C) .
Further, the tumors were often comprised of anaplastic, pleomorphic cells (Fig. 3D, 3E) , with one or multiple metastases to distant foci, including the lymph node (Fig. 3F) , lung (Fig. 3G), kidney (Fig. 3H), or liver (Fig. 3I) .
We compared the mean distribution-adjusted lesion grades of each lobe of the prostate gland among the control and low, medium and high Polyphenon E treatment groups of TRAMP mice. At 12 or 22 weeks of age, mean distribution-adjusted lesion grades of control and Polyphenon E treatment groups of TRAMP mice were not significantly different except within the lateral lobe of the 22 week old Polyphenon E treatment groups (Supplemental Fig. 2C) . A significant reduction of lesion progression in the lateral lobe of 22 week old Polyphenon E-treated TRAMP mice was observed (control vs treatment; 11.8±2.6 vs 8.8±2.0, P=0.004). At 32 weeks of age, the mean lesion grades of anterior, dorsal, and lateral lobes were significantly reduced in each of the low, medium, and high dose Polyphenon E-treated cohorts compared to untreated TRAMP controls, P=0.004, P=0.004, P=0.001, respectively (Supplemental Fig. 2A, 2B , and 2C).
Polyphenon E treatment clearly inhibited lesion progression to carcinoma when mean distribution-adjusted lesion grades of all prostatic lobes were considered together after 25 weeks of treatment from 7 to 32 weeks of age (Fig. 2B) . In addition, we observed a dose-dependent response in the mean distribution-adjusted lesion grades of the anterior and dorsal lobes, as well as the total prostate in TRAMP mice at this 32 week of age interval (Fig. 2B & Supplemental Fig. 2A & 2B) . These trends are (Fig. 2C) .
In hematology and serum biochemistry, the only differences noted between cohorts were platelet and albumin which were decreased 7-33% and 4-12%, respectively in the TRAMP mice administered a life-long high dose treatment of Polyphenon E as compared to the controls. Means of hemoglobin and serum calcium were also different among cohorts, but there was no discernable trend ( Table 2) .
MRI and US analysis:
MRI and US were used as a measure of tumor progression ( Fig. 4A and 4B) . The images were taken in sample mice at 32 weeks from (Fig. 4A) . The US images demonstrate decrease in the prostate tumor in the treated group (Fig. 4B) , which was significant between control and all treated mice (P<0.04) ( Table 3) .
During necropsy, ex vivo images of the prostate, seminal vesicles and kidneys were taken to show the final stage of the tumors in each treatment group. These images illustrate seminal vesicle involvement in each of the groups (Fig. 4C1-4 
Discussion
In this study we investigated the safety of Polyphenon E in C57BL/6J mice and its ability to inhibit the progression of PCa in the TRAMP mouse model. We showed that long-term treatment with Polyphenon E is safe and well tolerated with no evidence of toxicity to major organs, such as the lungs, liver and kidneys. Treatment with Polyphenon E at any dose significantly inhibited the progression of prostate lesion formation. Our findings provide additional evidence of the safety and chemopreventive effect of green tea on PCa and most significantly, the inhibition of PCa development and progression to distant organ metastasis.
The slow progression of PCa through initial hyperplasia to adenoma to adenocarcinoma and subsequently to metastatic disease provides an opportunity to intervene in the progression of the disease by chemoprevention. (41-44, 66, 67) show that long term use of a standardized GTC mixture such as Polyphenon E is safe and well tolerated with no adverse effect on major organs of the body, including the prostate.
Our finding that Polyphenon E inhibits the progression and metastasis of PCa in TRAMP mice is similar to that observed in previous studies using other GTC 
